VISION TIMELINE
†On average, people gained 5 letters at 1 month after their first treatment and gained and maintained 6 letters over 1 year on an eye chart with VABYSMO, similar to aflibercept 2 mg.
‡Maintained is defined as not losing 15 letters or more.
§In 2 clinical trials, VABYSMO was shown to reduce excess damaging fluid in the eye, similar to aflibercept 2 mg.
These results were not controlled for a possible type of statistical analysis error. Conclusions beyond the data shown should not be drawn.
VABYSMO was assessed in 2 clinical studies vs aflibercept 2 mg with 1329 people who were newly diagnosed with wet AMD.
TIME BETWEEN TREATMENTS
¶After 4 initial monthly eye injections, your doctor will choose a schedule of 1 to 4 months during your first year of treatment. Dosing may vary.
Although most people from the clinical trials went 3-4 months between injections, this may not be the experience of all people. Your retina specialist may evaluate your disease differently from the methods used in our trials.
Patient experiences may vary. Patient compensated by Genentech.
Explore our brochure for helpful information about VABYSMO and what to expect during treatment.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.